I have theT315I mutationbut also haveelevated lipaseTreatmentfor blastphaseCMLAfter 3months, I have3% BCR-ABL,I have this TKIresponseTKIs aremajorsubstratesfor this liverenzymePercentageof blastspresent inthe blastphaseI want toavoid thisTKI if I donot wantdiarrheaI avoid thisdrug classwith bosutinib,nilotinib anddasatinibI failed 3lines of TKIs,I can try thisagent nextThelandmarkfor thefirst TKIDrug classthatrevolutionizedCMLtreatmentNon-pharmacologicaltreatment forCMLModerateto highemetogenicrisk TKIsThe scoringsystem usedin chronicphaseThis TKI hasthe mostmetabolicsyndromeThe numberof distinctclinicalphases inCMLToo many ofthese bloodcells areabnormal inCMLPatients havepresence of thisBCR-ABLproteinindicative ofCML Therecommendedcriteria usedfor acceleratedphase60-70% ofpatients withCML presentwith thissymptomTranslocationbetweenthese twochromosomesoccur in CMLNumber ofblastspresent inacceleratedphaseWhen togive H2RAswithdasatinibResponsewhen BCR-ABL1 (IS)is <0.01%The current5-yearoverallsurvival rateof CMLI have theT315I mutationbut also haveelevated lipaseTreatmentfor blastphaseCMLAfter 3months, I have3% BCR-ABL,I have this TKIresponseTKIs aremajorsubstratesfor this liverenzymePercentageof blastspresent inthe blastphaseI want toavoid thisTKI if I donot wantdiarrheaI avoid thisdrug classwith bosutinib,nilotinib anddasatinibI failed 3lines of TKIs,I can try thisagent nextThelandmarkfor thefirst TKIDrug classthatrevolutionizedCMLtreatmentNon-pharmacologicaltreatment forCMLModerateto highemetogenicrisk TKIsThe scoringsystem usedin chronicphaseThis TKI hasthe mostmetabolicsyndromeThe numberof distinctclinicalphases inCMLToo many ofthese bloodcells areabnormal inCMLPatients havepresence of thisBCR-ABLproteinindicative ofCML Therecommendedcriteria usedfor acceleratedphase60-70% ofpatients withCML presentwith thissymptomTranslocationbetweenthese twochromosomesoccur in CMLNumber ofblastspresent inacceleratedphaseWhen togive H2RAswithdasatinibResponsewhen BCR-ABL1 (IS)is <0.01%The current5-yearoverallsurvival rateof CML

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
N
2
I
3
I
4
I
5
B
6
B
7
I
8
O
9
G
10
N
11
O
12
G
13
B
14
O
15
O
16
N
17
B
18
N
19
G
20
G
21
O
22
G
23
B
24
I
  1. N-I have the T315I mutation but also have elevated lipase
  2. I-Treatment for blast phase CML
  3. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  4. I-TKIs are major substrates for this liver enzyme
  5. B-Percentage of blasts present in the blast phase
  6. B-I want to avoid this TKI if I do not want diarrhea
  7. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  8. O-I failed 3 lines of TKIs, I can try this agent next
  9. G-The landmark for the first TKI
  10. N-Drug class that revolutionized CML treatment
  11. O-Non-pharmacological treatment for CML
  12. G-Moderate to high emetogenic risk TKIs
  13. B-The scoring system used in chronic phase
  14. O-This TKI has the most metabolic syndrome
  15. O-The number of distinct clinical phases in CML
  16. N-Too many of these blood cells are abnormal in CML
  17. B-Patients have presence of this BCR-ABL protein indicative of CML
  18. N-The recommended criteria used for accelerated phase
  19. G-60-70% of patients with CML present with this symptom
  20. G-Translocation between these two chromosomes occur in CML
  21. O-Number of blasts present in accelerated phase
  22. G-When to give H2RAs with dasatinib
  23. B-Response when BCR-ABL1 (IS) is <0.01%
  24. I-The current 5-year overall survival rate of CML